Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. The company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

A pioneer in the plasma industry, the company develops innovative plasma-derived medicines and other biopharmaceutical solutions that treat patients with chronic, rare and, at times, life-threatening conditions. It focuses on treating conditions centered on six core therapeutic areas: immunology, neurology, pulmonology, hematology, hepatology and intensive care.

Grifols has the world’s most diversified network of donation centers, with more than 400 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, the company offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. In addition, it supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

With more than 25,000 employees in more than 30 countries and regions, Grifols is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

For more information, please visit www.grifols.com